The financing supports Eliksa’s clinical development of ELK-003, a biological eye drop for ocular complications in Epidermolysis bullosa (EB) patients. The ongoing pilot study in cooperation with DEBRA Chile has enrolled 18 patients to date, with no drug-related side effects observed among the first 8 participants who have completed treatment.…
Read More
Patient-specific human immune system-bearing mouse model created by implanting human thymic cells derived from iPSC with Tolerance Bio’s proprietary process Human T cells educated in vivo by thymic organoids delayed melanoma tumor growth in a patient derived xenograft model Data support the development of Tolerance Bio’s thymic cells and pharmacological…
Read More
SEATTLE--(BUSINESS WIRE) --Kayothera, Inc. (“Kayothera”), a preclinical therapeutics company developing first-in-class, small molecule inhibitors of the retinoid nuclear receptor pathway, today announces that it has selected KAYO-1732 as a drug development candidate. KAYO-1732 is a novel, orally-available, small molecule inhibitor of the Aldehyde dehydrogenase 1A3 (ALDH1A3) enzyme, developed for the…
Read More
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics September 8, 2025 10:30 AM, PHILADELPHIA & BOSTON--(BUSINESS WIRE)--Tolerance Bio, a biopharmaceutical company pioneering innovative approaches to extending healthspan by preserving, restoring, and manipulating the function of the thymus, the master regulator of immune tolerance, and…
Read More
Summit Pharmaceuticals Signed an Exclusive Distributorship Agreement with Accelerated Biosciences, US Cell Provider Summit Pharmaceuticals International Corporation (Headquarters: Hitotsubashi, Chiyoda-ku, Tokyo, President & CEO: Katsuya Okuyama, hereinafter “SPI”) has signed an exclusive distributorship agreement with Accelerated Biosciences (Headquarters: Philadelphia, USA; CEO: Yuta Lee, hereinafter “AB”), a US-based company to expand…
Read More
Kayothera Named as a Winner of the American Diabetes Association’s Innovation Challenge to Transform Type 2 Diabetes Care Seattle, WA — June 21, 2025, Kayothera, Inc., a preclinical-stage therapeutics company pioneering first-in-class, oral inhibitors of the retinoid nuclear receptor pathway, today announced that it has been recognized as one of the…
Read More
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases World-class leaders in the thymus, immunology, oncology, cell therapy, and drug development will inform and support the Company’s efforts to preserve, restore, and manipulate the thymus to address…
Read More